Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Howard

Showing results (261-270 of 429) with videos related to

Pageof 43
Sort By:
Journal of the Neurological Sciences|October 19, 2024
Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravisSarah Dewilde, Alison Griffiths, Cynthia Z Qi, et al.
Biochimica Et Biophysica Acta|June 1, 1989
Transient chloramphenicol acetyltransferase expression of the G gamma globin gene 5'-flanking regions containing substitutions of C----T at position -158, G----A at position -161, and T----A at position -175 in K562 cellsK D Lanclos, S K Michael, Y C Gu, et al.
Journal of Neurology|March 8, 2023
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravisTuan Vu, Stephan Ortiz, Masahisa Katsuno, et al.
American Journal of Primatology|March 13, 1999
Islet cell antibodies in Sulawesi macaquesC F Howard, T Y Fang, C Southwick, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 11, 1991
Myasthenia gravis. T epitopes on the delta subunit of human muscle acetylcholine receptorM P Protti, A A Manfredi, X D Wu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 11, 1990
Use of synthetic peptides to establish anti-human acetylcholine receptor CD4+ cell lines from myasthenia gravis patientsM P Protti, A A Manfredi, C Straub, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1995
Immunoregulatory CD8+ cells recognize antigen-activated CD4+ cells in myasthenia gravis patients and in healthy controlsM H Yuen, M P Protti, B Diethelm-Okita, et al.
Journal of Clinical Apheresis|March 7, 2025
The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical CenterAshley J Crosby, Mariama Evans, Danielle L V Maracaja, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 18, 2006
Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vectorWilliam J Bowers, Michael A Mastrangelo, Darlene F Howard, et al.
Journal of Neurology|April 27, 2023
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extensionAndreas Meisel, Djillali Annane, Tuan Vu, et al.
Pageof 43

Showing results (261-270 of 429) with videos related to

Sort By:
Pageof 43
Journal of the Neurological Sciences|October 19, 2024
Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravisSarah Dewilde, Alison Griffiths, Cynthia Z Qi, et al.
Biochimica Et Biophysica Acta|June 1, 1989
Transient chloramphenicol acetyltransferase expression of the G gamma globin gene 5'-flanking regions containing substitutions of C----T at position -158, G----A at position -161, and T----A at position -175 in K562 cellsK D Lanclos, S K Michael, Y C Gu, et al.
Journal of Neurology|March 8, 2023
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravisTuan Vu, Stephan Ortiz, Masahisa Katsuno, et al.
American Journal of Primatology|March 13, 1999
Islet cell antibodies in Sulawesi macaquesC F Howard, T Y Fang, C Southwick, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 11, 1991
Myasthenia gravis. T epitopes on the delta subunit of human muscle acetylcholine receptorM P Protti, A A Manfredi, X D Wu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 11, 1990
Use of synthetic peptides to establish anti-human acetylcholine receptor CD4+ cell lines from myasthenia gravis patientsM P Protti, A A Manfredi, C Straub, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1995
Immunoregulatory CD8+ cells recognize antigen-activated CD4+ cells in myasthenia gravis patients and in healthy controlsM H Yuen, M P Protti, B Diethelm-Okita, et al.
Journal of Clinical Apheresis|March 7, 2025
The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical CenterAshley J Crosby, Mariama Evans, Danielle L V Maracaja, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 18, 2006
Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vectorWilliam J Bowers, Michael A Mastrangelo, Darlene F Howard, et al.
Journal of Neurology|April 27, 2023
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extensionAndreas Meisel, Djillali Annane, Tuan Vu, et al.
Pageof 43